DOCSLIB.ORG

Molecular Interactions Between Childhood Acute Lymphoblastic Leukaemia Cells and the Bone Marrow Microenvironment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Interactions Between Childhood Acute Lymphoblastic Leukaemia Cells and the Bone Marrow Microenvironment Molecular Interactions Between Childhood Acute Lymphoblastic Leukaemia Cells And The Bone Marrow Microenvironment Ana Markovic A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Children’s Cancer Institute Australia for Medical Research School of Women’s and Children’s Health THE UNIVERSITY OF NEW SOUTH WALES 2009 THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: MARKOVIC First name: ANA Other name/s: Abbreviation for degree as given in the University calendar: PhD School: Women’s & Children’s Health Faculty: MEDICINE Title: Molecular Interactions Between Childhood Acute Lymphoblastic Leukaemia Cells And The Bone Marrow Microenvironment. Abstract 350 words maximum Acute lymphoblastic leukaemia (ALL) is the most common cause of death from disease in children. Whilst cure rates over the last 30 years have drastically improved, children that do go on and relapse have a very poor prognosis. Additionally, the ones that do survive can have significant long term side effects from existing treatments. Understanding the molecular mechanisms of the relationship between leukaemia and its microenvironment is essential for the identification of novel targets for treatment and/or the manipulation of existing treatments. Our previous work has established a panel of childhood ALL xenografts from patient biopsies in NOD/SCID mice. Several samples secrete vascular endothelial growth factor (VEGF), an integral component of neovascularisation and normal haematopoiesis, and express FMS-like tyrosine kinase-3 (FLT-3), a receptor tyrosine kinase, which plays an essential role in regulating normal haematopoiesis. This thesis builds on previous work by examining the relationship between VEGF and FLT-3, two widely, yet independently studied molecules in leukaemia, with the aberrant expression of either having adverse outcomes for patients. The results show that the high expression and activation of FLT-3, significantly increases secretion of VEGF. To assess whether VEGF secretion is triggered by FLT-3 signalling, we measured VEGF in the absence and presence of an inhibitor (SU11657), humanised anti-FLT-3 blocking antibodies as well as decreasing the receptors with siRNA. All of these manipulations were able to decrease the secretion of VEGF in leukaemia cells. To further investigate this relationship, we examined the phosphorylation status of FLT-3 and the downstream signalling pathway. Our results indicate that FLT-3 signalling may be an important factor in the induction of VEGF secretion in a sub-type of leukaemia cells, and in turn, VEGF secretion can be attenuated by an FLT-3 specific inhibitor. Two separate microarray studies were also used to assess simultaneous gene expressions between the leukaemia and bone marrow microenvironment, and to examine the effects of FLT-3 ligand on ALL xenograft cells. The results of the microarray studies confirm the previously observed results regarding the manipulation of the microenvironment by the leukaemic cells. Inhibition of the FLT-3/VEGF pathway may disrupt paracrine signalling between leukaemia cells and the bone marrow microenvironment, and future studies into how this disruption may influence leukaemia cell responses to conventional chemotherapy are warranted. Declaration relating to disposition of project thesis/dissertation I hereby grant to the University of New South Wales or its agents the right to archive and to make available my thesis or dissertation in whole or in part in the University libraries in all forms of media, now or here after known, subject to the provisions of the Copyright Act 1968. I retain all property rights, such as patent rights. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation. I also authorise University Microfilms to use the 350 word abstract of my thesis in Dissertation Abstracts International (this is applicable to doctoral theses only). …………………………………………………… ……………………………………..……………… ……….………….. Signature Witness Date The University recognises that there may be exceptional circumstances requiring restrictions on copying or conditions on use. Requests for restriction for a period of up to 2 years must be made in writing. Requests for a longer period of restriction may be considered in exceptional circumstances and require the approval of the Dean of Graduate Research. FOR OFFICE USE ONLY Date of completion of requirements for Award: Declaration ORIGINALITY STATEMENT ‘I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom I have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project's design and conception or in style, presentation and linguistic expression is acknowledged.’ Signed ………………………………………………… Date …………………………………………………… Declaration iii Acknowledgements This thesis would not be possible without the support, belief and guidance of many people. I thank my supervisor A/Prof. Richard Lock for the opportunity he provided to undertake this work, along with Dr. Karen Mackenzie for her support. I have learned a great deal during my time at the Children's Cancer Institute Australia. I would also like to acknowledge the Berry family together with the Australian Academy of Science and the Foundation of the National Institutes of Health for establishing the fellowship which enabled me to experience working at the NIH. This includes, in particular, Dr. Javed Khan and his lab for accepting me for the short time I was there and teaching me about microarrays. I thank the staff at the faculty of Science at the University of NSW, for giving me the opportunity to experience the joy of teaching. Also, I want to thank the friends that have stayed by me in this madness, otherwise known as a PhD; especially Dr. Marina Pajic, Dr. Scott Melville and Laura Veas. Thank you to Dr. Andrew Kinsela, who has learned more about leukaemia, more than he ever thought he would or even wanted to know. Thank you, I am very grateful for all your love and support. Looks like I too have made it to the end. A thank you also needs to go to my grandparents. I am just sorry my grandfather is not here to see the completion of this thesis. Finally my mum and dad and my brother Ivan – thank you, I love you. Acknowledgements v Conferences, Publications and Awards Conferences Markovic A, MacKenzie KL, Lock RB. (2007) Induction of vascular endothelial growth factor secretion in acute leukemia cells via the FLT-3 signaling pathway, AACR- NIH-EORTC Conference “Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, San Francisco, USA. Markovic A, MacKenzie KL, Lock RB. (2007) Induction of VEGF Secretion in Acute Leukaemia Cells Through the FLT-3 Signalling Pathway, 19th Lorne Cancer Conference, Lorne, Victoria, Australia. Markovic A, MacKenzie KL, Lock RB. (2006) Novel Function of FLT-3: Induction of the Vascular Endothelial Growth Factor in Acute Leukaemia, Australian Society for Medical Research annual NSW Meeting, Sydney, Australia. Markovic A. (2005) Experience at the NIH as the Inaugural Recipient of the Adam J. Berry Memorial Fellowship, Annual Meeting of the Australian Academy of Science, Canberra, Australia. Conferences, Publications and Awards vii Publications Markovic A, MacKenzie KL, Lock RB. FLT-3: a new focus in the understanding of acute leukemia. Int J Biochem Cell Biol. 37(6):1168-72. Markovic A, MacKenzie KL, Lock RB. Induction of VEGF in leukaemia cells (manuscript in preparation) Awards 2007 - AACR Eli-Lilly Travel Award, for the conference AACR-NIH-EORTC Conference “Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, San Francisco, USA. 2005 - Australian Academy of Science & the Foundation for the National Institutes of Health USA - Inaugural Recipient of the Adam J. Berry Memorial Fellowship Conferences, Publications and Awards viii Abstract Acute lymphoblastic leukaemia (ALL) is the most common cause from death of disease in children. Whilst cure rates over the last 30 years have drastically improved, the children that do go on and relapse have a very poor prognosis. Additionally, the ones that do survive can have significant long term side effects from existing treatments. Understanding the molecular mechanisms of the relationship between leukaemia and its microenvironment is essential for the identification of novel targets for treatment and/or the manipulation of existing treatments. The role that vascular endothelial growth factor (VEGF), an integral component of both neovascularisation and normal haematopoiesis, plays in the progression and invasiveness of solid tumours is well established. However, its function in haematological malignancies has been a more recent and thus less considered observation. Human leukaemia cells secrete VEGF, which may act in a paracrine manner with the bone marrow microenvironment to promote the survival and proliferation of leukaemia cells. In addition to VEGF being produced by leukaemias, it also increases
Load more

Recommended publications
  • Cytogenomic SNP Microarray - Fetal ARUP Test Code 2002366 Maternal Contamination Study Fetal Spec Fetal Cells
    Patient Report |FINAL Client: Example Client ABC123 Patient: Patient, Example 123 Test Drive Salt Lake City, UT 84108 DOB 2/13/1987 UNITED STATES Gender: Female Patient Identifiers: 01234567890ABCD, 012345 Physician: Doctor, Example Visit Number (FIN): 01234567890ABCD Collection Date: 00/00/0000 00:00 Cytogenomic SNP Microarray - Fetal ARUP test code 2002366 Maternal Contamination Study Fetal Spec Fetal Cells Single fetal genotype present; no maternal cells present. Fetal and maternal samples were tested using STR markers to rule out maternal cell contamination. This result has been reviewed and approved by Maternal Specimen Yes Cytogenomic SNP Microarray - Fetal Abnormal * (Ref Interval: Normal) Test Performed: Cytogenomic SNP Microarray- Fetal (ARRAY FE) Specimen Type: Direct (uncultured) villi Indication for Testing: Patient with 46,XX,t(4;13)(p16.3;q12) (Quest: EN935475D) ----------------------------------------------------------------- ----- RESULT SUMMARY Abnormal Microarray Result (Male) Unbalanced Translocation Involving Chromosomes 4 and 13 Classification: Pathogenic 4p Terminal Deletion (Wolf-Hirschhorn syndrome) Copy number change: 4p16.3p16.2 loss Size: 5.1 Mb 13q Proximal Region Deletion Copy number change: 13q11q12.12 loss Size: 6.1 Mb ----------------------------------------------------------------- ----- RESULT DESCRIPTION This analysis showed a terminal deletion (1 copy present) involving chromosome 4 within 4p16.3p16.2 and a proximal interstitial deletion (1 copy present) involving chromosome 13 within 13q11q12.12. This
    [Show full text]
  • Childhood Leukemia
    Onconurse.com Fact Sheet Childhood Leukemia The word leukemia literally means “white blood.” fungi. WBCs are produced and stored in the bone mar- Leukemia is the term used to describe cancer of the row and are released when needed by the body. If an blood-forming tissues known as bone marrow. This infection is present, the body produces extra WBCs. spongy material fills the long bones in the body and There are two main types of WBCs: produces blood cells. In leukemia, the bone marrow • Lymphocytes. There are two types that interact to factory creates an overabundance of diseased white prevent infection, fight viruses and fungi, and pro- cells that cannot perform their normal function of fight- vide immunity to disease: ing infection. As the bone marrow becomes packed with diseased white cells, production of red cells (which ° T cells attack infected cells, foreign tissue, carry oxygen and nutrients to body tissues) and and cancer cells. platelets (which help form clots to stop bleeding) slows B cells produce antibodies which destroy and stops. This results in a low red blood cell count ° foreign substances. (anemia) and a low platelet count (thrombocytopenia). • Granulocytes. There are four types that are the first Leukemia is a disease of the blood defense against infection: Blood is a vital liquid which supplies oxygen, food, hor- ° Monocytes are cells that contain enzymes that mones, and other necessary chemicals to all of the kill foreign bacteria. body’s cells. It also removes toxins and other waste products from the cells. Blood helps the lymph system ° Neutrophils are the most numerous WBCs to fight infection and carries the cells necessary for and are important in responding to foreign repairing injuries.
    [Show full text]
  • Late Effects Among Long-Term Survivors of Childhood Acute Leukemia in the Netherlands: a Dutch Childhood Leukemia Study Group Report
    0031-3998/95/3805-0802$03.00/0 PEDIATRIC RESEARCH Vol. 38, No.5, 1995 Copyright © 1995 International Pediatric Research Foundation, Inc. Printed in U.S.A. Late Effects among Long-Term Survivors of Childhood Acute Leukemia in The Netherlands: A Dutch Childhood Leukemia Study Group Report A. VAN DER DOES-VAN DEN BERG, G. A. M. DE VAAN, J. F. VAN WEERDEN, K. HAHLEN, M. VAN WEEL-SIPMAN, AND A. J. P. VEERMAN Dutch Childhood Leukemia Study Group,' The Hague, The Netherlands A.8STRAC ' Late events and side effects are reported in 392 children cured urogenital, or gastrointestinal tract diseases or an increased vul­ of leukemia. They originated from 1193 consecutively newly nerability of the musculoskeletal system was found. However, diagnosed children between 1972 and 1982, in first continuous prolonged follow-up is necessary to study the full-scale late complete remission for at least 6 y after diagnosis, and were effects of cytostatic treatment and radiotherapy administered treated according to Dutch Childhood Leukemia Study Group during childhood. (Pediatr Res 38: 802-807, 1995) protocols (70%) or institutional protocols (30%), all including cranial irradiation for CNS prophylaxis. Data on late events (relapses, death in complete remission, and second malignancies) Abbreviations were collected prospectively after treatment; late side effects ALL, acute lymphocytic leukemia were retrospectively collected by a questionnaire, completed by ANLL, acute nonlymphocytic leukemia the responsible pediatrician. The event-free survival of the 6-y CCR, continuous first complete remission survivors at 15 y after diagnosis was 92% (±2%). Eight late DCLSG, Dutch Childhood Leukemia Study Group relapses and nine second malignancies were diagnosed, two EFS, event free survival children died in first complete remission of late toxicity of HR, high risk treatment, and one child died in a car accident.
    [Show full text]
  • Health | Childhood Cancer America's Children and the Environment
    Health | Childhood Cancer Childhood Cancer Cancer is not a single disease, but includes a variety of malignancies in which abnormal cells divide in an uncontrolled manner. These cancer cells can invade nearby tissues and can migrate by way of the blood or lymph systems to other parts of the body.1 The most common childhood cancers are leukemias (cancers of the white blood cells) and cancers of the brain or central nervous system, which together account for more than half of new childhood cancer cases.2 Cancer in childhood is rare compared with cancer in adults, but still causes more deaths than any factor, other than injuries, among children from infancy to age 15 years.2 The annual incidence of childhood cancer has increased slightly over the last 30 years; however, mortality has declined significantly for many cancers due largely to improvements in treatment.2,3 Part of the increase in incidence may be explained by better diagnostic imaging or changing classification of tumors, specifically brain tumors.4 However, the President’s Cancer Panel recently concluded that the causes of the increased incidence of childhood cancers are not fully understood, and cannot be explained solely by the introduction of better diagnostic techniques. The Panel also concluded that genetics cannot account for this rapid change. The proportion of this increase caused by environmental factors has not yet been determined.5 The causes of cancer in children are poorly understood, though in general it is thought that different forms of cancer have different causes. According to scientists at the National Cancer Institute, established risk factors for the development of childhood cancer include family history, specific genetic syndromes (such as Down syndrome), high levels of radiation, and certain pharmaceutical agents used in chemotherapy.4,6 A number of studies suggest that environmental contaminants may play a role in the development of childhood cancers.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • A Flexible Microfluidic System for Single-Cell Transcriptome Profiling
    www.nature.com/scientificreports OPEN A fexible microfuidic system for single‑cell transcriptome profling elucidates phased transcriptional regulators of cell cycle Karen Davey1,7, Daniel Wong2,7, Filip Konopacki2, Eugene Kwa1, Tony Ly3, Heike Fiegler2 & Christopher R. Sibley 1,4,5,6* Single cell transcriptome profling has emerged as a breakthrough technology for the high‑resolution understanding of complex cellular systems. Here we report a fexible, cost‑efective and user‑ friendly droplet‑based microfuidics system, called the Nadia Instrument, that can allow 3′ mRNA capture of ~ 50,000 single cells or individual nuclei in a single run. The precise pressure‑based system demonstrates highly reproducible droplet size, low doublet rates and high mRNA capture efciencies that compare favorably in the feld. Moreover, when combined with the Nadia Innovate, the system can be transformed into an adaptable setup that enables use of diferent bufers and barcoded bead confgurations to facilitate diverse applications. Finally, by 3′ mRNA profling asynchronous human and mouse cells at diferent phases of the cell cycle, we demonstrate the system’s ability to readily distinguish distinct cell populations and infer underlying transcriptional regulatory networks. Notably this provided supportive evidence for multiple transcription factors that had little or no known link to the cell cycle (e.g. DRAP1, ZKSCAN1 and CEBPZ). In summary, the Nadia platform represents a promising and fexible technology for future transcriptomic studies, and other related applications, at cell resolution. Single cell transcriptome profling has recently emerged as a breakthrough technology for understanding how cellular heterogeneity contributes to complex biological systems. Indeed, cultured cells, microorganisms, biopsies, blood and other tissues can be rapidly profled for quantifcation of gene expression at cell resolution.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • DULIP: a Dual Luminescence-Based Co-Immunoprecipitation Assay for Interactome Mapping in Mammalian Cells
    Repository of the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association http://edoc.mdc-berlin.de/14998 DULIP: A dual luminescence-based co-immunoprecipitation assay for interactome mapping in mammalian cells Trepte, P., Buntru, A., Klockmeier, K., Willmore, L., Arumughan, A., Secker, C., Zenkner, M., Brusendorf, L., Rau, K., Redel, A., Wanker, E.E. NOTICE: this is the author’s version of a work that was accepted for publication in the Journal of Molecular Biology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in: Journal of Molecular Biology 2015 MMM DD ; 427(21): 3375-3388 doi: 10.1016/j.jmb.2015.08.003 Publisher: Elsevier © 2015, Elsevier. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA. DULIP: A DUAL LUMINESCENCE-BASED CO-IMMUNOPRECIPITATION ASSAY FOR INTERACTOME MAPPING IN MAMMALIAN CELLS Philipp Treptea, Alexander Buntrua#, Konrad Klockmeiera#, Lindsay Willmorea, Anup Arumughana, Christopher Seckera, Martina Zenknera, Lydia Brusendorfa, Kirstin Raua, Alexandra Redela and Erich E Wankera* a Neuroproteomics, Max Delbrueck Center for Molecular Medicine, Robert-Roessle- Straße 10, 13125 Berlin, Germany # Contributed equally * Corresponding author, E-mail address: [email protected], Telephone: +49- 30-9406-2157, Fax: +49-30-9406-2552 ABSTRACT Mapping of protein-protein interactions (PPIs) is critical for understanding protein function and complex biological processes.
    [Show full text]
  • Supplementary Figure S4
    18DCIS 18IDC Supplementary FigureS4 22DCIS 22IDC C D B A E (0.77) (0.78) 16DCIS 14DCIS 28DCIS 16IDC 28IDC (0.43) (0.49) 0 ADAMTS12 (p.E1469K) 14IDC ERBB2, LASP1,CDK12( CCNE1 ( NUTM2B SDHC,FCGR2B,PBX1,TPR( CD1D, B4GALT3, BCL9, FLG,NUP21OL,TPM3,TDRD10,RIT1,LMNA,PRCC,NTRK1 0 ADAMTS16 (p.E67K) (0.67) (0.89) (0.54) 0 ARHGEF38 (p.P179Hfs*29) 0 ATG9B (p.P823S) (0.68) (1.0) ARID5B, CCDC6 CCNE1, TSHZ3,CEP89 CREB3L2,TRIM24 BRAF, EGFR (7p11); 0 ABRACL (p.R35H) 0 CATSPER1 (p.P152H) 0 ADAMTS18 (p.Y799C) 19q12 0 CCDC88C (p.X1371_splice) (0) 0 ADRA1A (p.P327L) (10q22.3) 0 CCNF (p.D637N) −4 −2 −4 −2 0 AKAP4 (p.G454A) 0 CDYL (p.Y353Lfs*5) −4 −2 Log2 Ratio Log2 Ratio −4 −2 Log2 Ratio Log2 Ratio 0 2 4 0 2 4 0 ARID2 (p.R1068H) 0 COL27A1 (p.G646E) 0 2 4 0 2 4 2 EDRF1 (p.E521K) 0 ARPP21 (p.P791L) ) 0 DDX11 (p.E78K) 2 GPR101, p.A174V 0 ARPP21 (p.P791T) 0 DMGDH (p.W606C) 5 ANP32B, p.G237S 16IDC (Ploidy:2.01) 16DCIS (Ploidy:2.02) 14IDC (Ploidy:2.01) 14DCIS (Ploidy:2.9) -3 -2 -1 -3 -2 -1 -3 -2 -1 -3 -2 -1 -3 -2 -1 -3 -2 -1 Log Ratio Log Ratio Log Ratio Log Ratio 12DCIS 0 ASPM (p.S222T) Log Ratio Log Ratio 0 FMN2 (p.G941A) 20 1 2 3 2 0 1 2 3 2 ERBB3 (p.D297Y) 2 0 1 2 3 20 1 2 3 0 ATRX (p.L1276I) 20 1 2 3 2 0 1 2 3 0 GALNT18 (p.F92L) 2 MAPK4, p.H147Y 0 GALNTL6 (p.E236K) 5 C11orf1, p.Y53C (10q21.2); 0 ATRX (p.R1401W) PIK3CA, p.H1047R 28IDC (Ploidy:2.0) 28DCIS (Ploidy:2.0) 22IDC (Ploidy:3.7) 22DCIS (Ploidy:4.1) 18IDC (Ploidy:3.9) 18DCIS (Ploidy:2.3) 17q12 0 HCFC1 (p.S2025C) 2 LCMT1 (p.S34A) 0 ATXN7L2 (p.X453_splice) SPEN, p.P677Lfs*13 CBFB 1 2 3 4 5 6 7 8 9 10 11
    [Show full text]
  • High-Resolution Analysis of Chromosomal Breakpoints and Genomic Instability Identifies PTPRD As a Candidate Tumor Suppressor Gene in Neuroblastoma
    Research Article High-Resolution Analysis of Chromosomal Breakpoints and Genomic Instability Identifies PTPRD as a Candidate Tumor Suppressor Gene in Neuroblastoma Raymond L. Stallings,1 Prakash Nair,1 John M. Maris,2 Daniel Catchpoole,3 Michael McDermott,4 Anne O’Meara,5 and Fin Breatnach5 1Children’s Cancer Research Institute and Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, Texas; 2Division of Oncology, Children’s Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; 3The Tumor Bank, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; and Departments of 4Pathology and 5Oncology, Our Lady’s Hospital for Sick Children, Dublin, Ireland Abstract and death from disease. Patient age, tumor stage, and several Although neuroblastoma is characterized by numerous different genetic abnormalities are important factors that influence clinical outcome. Loss of 1p and 11q, gain of 17q, and amplification recurrent, large-scale chromosomal imbalances, the genes MYCN targeted by such imbalances have remained elusive. We have of the oncogene are particularly strong genetic indicators of poor disease outcome (2–5). Two of these abnormalities, loss of 11q applied whole-genome oligonucleotide array comparative MYCN genomic hybridization (median probe spacing 6 kb) to 56 and amplification, form the basis for dividing advanced- stage neuroblastomas into genetic subtypes due to their rather neuroblastoma tumors and cell lines to identify genes involved with disease pathogenesis. This set oftumors was selected for striking inverse distribution in tumors (6, 7). Many other recurrent having either 11q loss or MYCN amplification, abnormalities partial chromosomal imbalances, including loss of 3p, 4p, 9p, and that define the two most common genetic subtypes of 14q and gain of 1q, 2p, 7q, and 11p, have been identified by metastatic neuroblastoma.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]